Thank you.

We have now filled all Gala Dinner 2018 supporter places, and would like to thank the following organisations for supporting the 2018 Gala Dinner.

Please email Dannielle to enquire about supporting Gala Dinner 2019.


Abzena provides proprietary technologies and complementary services in the UK and US to enable the development and manufacture of biopharmaceuticals. 

The Group comprises Antitope, PacificGMP and PolyTherics, which between them have built a global customer base including the majority of the top 20 biopharmaceutical companies as well as many large and small biotech companies and leading academic research institutions.

Antitope provides immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture.

PacificGMP provides contract process development and manufacture of biopharmaceuticals, including monoclonal antibodies, recombinant proteins, vaccines, and gene therapy and cell therapy products, for preclinical and clinical studies.

PolyTherics specializes in proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimizing the therapeutic properties of biopharmaceuticals.

Abzena has its main operations in Cambridge, UK and in San Diego, CA, USA. The shares of Abzena plc are quoted on the AIM segment of the London Stock Exchange under the symbol ABZA.


Funded by Government, BBSRC invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond by helping society to meet major challenges, including green energy, food security and healthier, longer lives.

Industrial Biotechnology and Bioenergy (IBBE) is one of BBSRC’s three strategic priority areas. BBSRC is actively working with partners to build a thriving IBBE sector and last year invested £50.4 million into research and innovation around energy, chemicals and biopharmaceuticals. Through BBSRC’s Networks in Industrial Biotechnology and Bioenergy (BBSRC NIBB) more than 600 companies are currently engaged in collaborative working with over 2,600 academics to find new approaches to tackle research challenges, translate research and deliver key benefits in IBBE.


With more than 35 years representing life sciences clients, Cooley has been at the forefront working alongside leading life sciences companies across the globe. Our clients include both high-growth and mature companies as well as entrepreneurs, venture capitalists and financial institutions. We represent more than 1,200 life sciences companies and medical technologies companies worldwide. 

Cooley has been involved with hundreds of transactions across various technologies and stages of product development and are widely recognized as best-in-class in handling corporate partnering and licensing transactions. We have handled more than 1,000 M&A transactions since 2010 and understand unique structuring issues for life sciences companies, including milestone structures, contingent value rights and option structures. We are the #1 ranking firm in the representation of U.S. issuer-side life science IPOs since 2000 per IPO Vital Signs.  Our team includes leading regulatory lawyers and over 70 life sciences patent lawyers and professionals.



Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation – JLABS, Johnson & Johnson Innovation – JLINX, Johnson & Johnson Innovation – JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit or follow @JNJInnovation.


Summit is a UK company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need. 

Summit is a UK based drug discovery and development Company focused on producing innovative medicines to treat areas of high unmet medical need. Summit is developing high-quality, differentiated programmes that seek to provide the Company with the opportunity of maximising their therapeutic and commercial potential for the benefit of patients and shareholders.

Summit’s current therapeutic focus is on the rare disease Duchenne muscular dystrophy (DMD) and the infectious disease caused by the bacteria C. difficile. Summit has established leadership positions in these two therapy areas that are enhanced through formation of strong partnerships with a range of leading academic groups, clinicians and community advocacy foundations.